NFKB1 and neoplasm: ,181 Bortezomib, which has the ability to inhibit NF-κB signaling pathways and thus affect tumor occurrence, has also been reported in a variety of cancers including renal cancer, head and neck squamous cell carcinomas, and ovarian cancer.124, 125, 126